P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST-IN-CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2-MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND-01 TRIAL. (23rd June 2022) - Martinelli, G.; Santoro, A.; Gambacorti-Passerini, C.; Vives Polo, S.; Solomon, S. R.; Mukherjee, S.; Lech-Maranda, E.; Yair Levy, M.; Wierzbowska, A.; Calbacho-Robles, M.; Marconi, G.; Benedetta Giannini, M.; et al.